Adarx Pharmaceuticals, Inc.: UBS initiates coverage with buy rating; target price $35
ADRX•UBS initiated coverage of Adarx Pharmaceuticals, Inc. with a buy rating and a $35 target price.
Related News
European Commission approves Keytruda plus Padcev for adults with resectable muscle-invasive bladder cancer
MRK•
Northern Trust announces third-quarter 2026 financial results release
NTRS•
BankUnited's Q3 adjusted EPS misses estimates, non-interest income declines
BKU•
INmune Bio partners with Uniphar for international access to Ebstrocel
INMB•
Array Technologies Inc: BMO cuts target price to $6 from $7
ARRY•